MMP9 and liver dysplastic nodule: Using urine obtained from the Mehdi et al. clinical trial (57), we have shown that the addition of MR antagonism to maximal ACE inhibition in patients with DN reduced urine active MMP2 and MMP9 compared with placebo, with an associated reduction in albuminuria.